MacroPore Biosurgery, Inc. Awarded $750,000 From National Institutes of Health (NIH) To Continue Studying The Use Of Adipose-Derived Regenerative Cells For Treating Heart Attack

MacroPore Biosurgery Inc. (Frankfurt:XMP) (Reuters: MACP.DE) (XMP:GR) announced today that it has been awarded $750,000 to continue with the second phase of its National Institutes of Health (NIH) Small Business Innovation Research (SBIR) grant. This grant is for the study of the potential role of adipose-derived regenerative cells in treating heart attack and to support future application of these cells in human clinical trials. The second phase follows the successful completion of the first phase, which included an award of $100,000. The research is being conducted in collaboration with W. Robb MacLellan M.D. at the David Geffen School of Medicine at the University of California, Los Angeles.